- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07942038
Myocardial Fibrosis and Deformation Kinetics After the Ross Procedure Using Cardiac MRI
Myocardial Tissue Characterization and Deformation Kinetics Following the Ross Procedure: A Prospective Multiparametric CMR Study
The Ross procedure entails pulmonary autograft replacement of the aortic valve, primarily indicated in pediatric and young adult cohorts presenting with severe aortic valve disease. Despite postoperative preservation of left ventricular ejection fraction (LVEF) on resting transthoracic echocardiography, a subset of recipients exhibits blunted peak oxygen consumption (peak VO2), subclinical electromechanical dyssynchrony, and ventricular arrhythmias.
Chronic severe aortic valve pathology induces distinct myocardial remodeling patterns. Chronic pressure overload (aortic stenosis) triggers concentric cardiomyocyte hypertrophy and diffuse interstitial fibrosis. Chronic volume overload (aortic regurgitation) induces eccentric left ventricular dilatation and extracellular matrix degradation with collagen disarray. Following surgical hemodynamic unloading, left ventricular mass regresses; however, the extent of diffuse interstitial collagen matrix resorption versus pure cardiomyocyte cellular volume regression remains uncharacterized in this demographic.
This prospective longitudinal study employs multiparametric cardiovascular magnetic resonance (CMR) imaging to evaluate myocardial tissue characterization and deformation kinetics in young adults undergoing the Ross procedure. Participants will undergo contrast-enhanced CMR at baseline and at 12 months postoperatively. Quantitative endpoints include native T1 mapping, extracellular volume fraction (ECV), indexed extracellular volume (iECV), and three-dimensional (3D) feature-tracking strain (global longitudinal, circumferential, and radial strain). The primary objective is to correlate the resolution of diffuse microscopic fibrosis with subclinical mechanical recovery, comparing remodeling trajectories between pressure-overloaded and volume-overloaded phenotypes.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
The study population comprises patients presenting with severe primary aortic valve disease-specifically chronic pressure overload (severe aortic stenosis) or chronic volume overload (severe aortic regurgitation)-who are scheduled for an elective full-root Ross procedure (pulmonary autograft replacement of the aortic valve). Patients are recruited prospectively and are evaluated without a history of obstructive coronary artery disease, prior myocardial infarction, primary non-ischemic cardiomyopathy, or systemic connective tissue disorders.
Descripción
Inclusion Criteria:
- Severe primary aortic valve stenosis, regurgitation, or mixed lesion scheduled for an elective Ross procedure.
- Informed written consent to participate in serial prospective imaging.
Exclusion Criteria:
- Documented coronary artery disease (≥ 50% stenosis or previous coronary revascularization).
- Prior myocardial infarction or primary non-ischemic cardiomyopathy.
- Severe renal impairment (estimated Glomerular Filtration Rate < 30 mL/min/1.73 m²).
- Associated congenital heart disease causing volume overload ex: VSD and PDA.
- Systemic connective tissue disorders (Marfan, Loeys-Dietz, or Ehlers-Danlos syndromes).
- Standard contraindications to contrast-enhanced CMR (incompatible ferromagnetic implants, severe claustrophobia).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Diffuse myocardial fibrosis
Periodo de tiempo: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Quantify the serial longitudinal changes in diffuse myocardial interstitial fibrosis-measured by indexed extracellular volume (iECV, in mL/m²)-from baseline to 12 months postoperatively in young adults undergoing the Ross procedure. |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Diffuse myocardial fibrosis
Periodo de tiempo: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Quantify the serial longitudinal changes in diffuse myocardial interstitial fibrosis-measured by extracellular volume fraction (ECV, in %) |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Subclinical myocardial mechanical recovery
Periodo de tiempo: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured by 3D CMR feature-tracking strain analysis by 3D global longitudinal strain (3D-GLS) |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Subclinical myocardial mechanical recovery
Periodo de tiempo: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured by 3D CMR feature-tracking strain analysis by 3D global circular strain (3D-GCS) |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Subclinical myocardial mechanical recovery
Periodo de tiempo: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured by 3D CMR feature-tracking strain analysis by global radial strain [GRS]. |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
|
Subclinical myocardial mechanical recovery
Periodo de tiempo: Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Measured through 3D CMR feature-tracking strain analysis by peak diastolic strain rate. |
Baseline up to two weeks before ROSS procedure and 1 year postoperatively.
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- CMR-ROSS
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .